NCT05567185 2026-04-13
TAR-210
Janssen Pharmaceutical K.K.
Phase 1 Active not recruiting
Clinical Trials
8 trialsNCT04572295 2026-03-11
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
Eisai Inc.
Phase 1 Active not recruiting
NCT03144661 2025-10-21
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Incyte Corporation
Phase 1 Terminated
NCT01703481 2025-02-03
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
Janssen Research & Development, LLC
Phase 1 Completed
NCT06160752 2024-10-03
SURF201
Tyra Biosciences, Inc
Phase 1 Recruiting
NCT04972253 2022-08-10
(BLASST)-3
Dana-Farber Cancer Institute
Phase 1 Withdrawn
NCT01928459 2020-12-09
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
Novartis
Phase 1 Completed
NCT03235570 2020-05-29
A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)
Incyte Corporation
Phase 1 Completed